Targeting B16 tumors in vivo with peptide-conjugated gold nanoparticles

Nanotechnology

Volumn 26, Issue 28, 2015, Pages

  Poon, Wilson ^a   Zhang, Xuan ^a   Bekah, Devesh ^a   Teodoro, Jose G ^a,b   Nadeau, Jay L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

cancer; EPR effect; gold nanoparticles; melanoma; peptide targeting

Indexed keywords

CELL CULTURE; CYTOTOXICITY; DERMATOLOGY; FIBER OPTIC SENSORS; GOLD; MASS SPECTROMETRY; METAL NANOPARTICLES; NANOPARTICLES; ONCOLOGY; TUMORS; VIRUSES;

BIODISTRIBUTIONS; BLOOD-BRAIN BARRIER; CANCER; CYTOTOXIC ACTIVITIES; EPR EFFECT; GOLD NANOPARTICLES; MELANOMA; PASSIVE TARGETING;

PEPTIDES;

CYCLIC ARGININE-GLYCINE-ASPARTIC ACID PEPTIDE; CYCLOPEPTIDE; GOLD; MACROGOL DERIVATIVE; METAL NANOPARTICLE; PEPTIDE;

ALLOGRAFT; ANIMAL; BODY FLUID; CHEMISTRY; DRUG DELIVERY SYSTEM; EXPERIMENTAL MELANOMA; MOUSE; MYXOMA VIRUS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ALLOGRAFTS; ANIMALS; BODY FLUIDS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GOLD; MELANOMA, EXPERIMENTAL; METAL NANOPARTICLES; MICE; MYXOMA VIRUS; PEPTIDES; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION;

EID: 84937148108     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/26/28/285101     Document Type: Article

References (23)

1. Agemy L, Friedmann-Morvinski D, Kotamraju V R, Roth L, Sugahara K N, Girard O M, Mattrey R F, Verma I M and Ruoslahti E 2011 Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma Proc. Natl Acad. Sci. 108 17450-5
2. Almansour N M, Pirogova E, Coloe P J, Cosic I and Istivan T S 2012 A bioactive peptide analogue for myxoma virus protein with a targeted cytotoxicity for human skin cancer in vitro J. Biomed. Sci. 19 65
3. Bartczak D and Kanaras A G 2011 Preparation of peptide-functionalized gold nanoparticles using one pot EDC/sulfo-NHS coupling Langmuir 27 10119-23
4. Buerkle M, Pahernik S, Sutter A, Jonczyk A, Messmer K and Dellian M 2002 Inhibition of the alpha-ν integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo Br. J. Cancer 86 788-95
5. Clarke S J, Hollmann C, Aldaye F A and Nadeau J L 2008 Effect of ligand density on the spectral, physical, and biological characteristics of CdSe/ZnS quantum dots Bioconjugate Chem. 19 562-8
6. Deutscher S L 2010 Phage display in molecular imaging and diagnosis of cancer Chem. Rev. 110 3196-211
7. Dubey P K, Mishra V, Jain S, Mahor S and Vyas S 2004 Liposomes modified with cyclic RGD peptide for tumor targeting J. Drug Targeting 12 257-64
8. Eggermont A M and Robert C 2011 New drugs in melanoma: it'sa whole new wor Eur. J. Cancer 47 2150-7
9. Gormley A J, Malugin A, Ray A, Robinson R and Ghandehari H 2011 Biological evaluation of RGDfK-gold nanorod conjugates for prostate cancer treatment J. Drug Targeting 19 915-24
10. Hamad I, Al-Hanbali O, Hunter A C, Rutt K J, Andresen T L and Moghimi S M 2010 Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering ACS Nano 4 6629-38
11. Huang K et al 2012 Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo ACS Nano 6 4483-93
12. Istivan T S, Pirogova E, Gan E, Almansour N M, Coloe P J and Cosic I 2011 Biological effects of a de novo designed myxoma virus peptide analogue: evaluation of cytotoxicity on tumor cells PLoS One 6 e24809
13. Mosqueira V C F, Legrand P, Gulik A, Bourdon O, Gref R, Labarre D and Barratt G 2001 Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules Biomaterials 22 2967-79
14. Ruoslahti E and Pierschbacher M D 1986 Arg-Gly-Asp: a versatile cell recognition signal Cell 44 517-8
15. Sato A K, Viswanathan M, Kent R B and Wood C R 2006 Therapeutic peptides: technological advances driving peptides into development Curr. Opin. Biotechnol. 17 638-42
16. Smith A M, Duan H, Mohs A M and Nie S 2008 Bioconjugated quantum dots for in vivo molecular and cellular imaging Adv. Drug Deliv. Rev. 60 1226-40
17. Souris J S, Lee C H, Cheng S H, Chen C T, Yang C S, Ho J A, Mou C Y and Lo L W 2010 Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles Biomaterials 31 5564-74
18. Stanford M M and McFadden G 2007 Expert Opin. Biol. Ther. 7 1415-25 Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer
19. Stanford M M, Shaban M, Barrett J W, Werden S J, Gilbert P-A, Bondy-Denomy J, MacKenzie L, Graham K C, Chambers A F and McFadden G 2007 Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo Mol. Ther. 16 52-9
20. Sun J, Luo C, Wang Y and He Z 2013 The holistic 3 M modality of drug delivery nanosystems for cancer therapy Nanoscale 5 845-59
21. Verma A and Stellacci F 2010 Effect of surface properties on nanoparticle-cell interactions Small 6 12-21
22. Zako T, Nagata H, Terada N, Utsumi A, Sakono M, Yohda M, Ueda H, Soga K and Maeda M 2009 Cyclic RGD peptide-labeled upconversion nanophosphors for tumor cell-targeted imaging Biochem. Biophys. Res. Commun. 381 54-8
23. Zhang X, Chibli H, Mielke R and Nadeau J 2011 Ultrasmall gold-doxorubicin conjugates rapidly kill apoptosis-resistant cancer cells Bioconjugate Chem. 22 235-43